一般外科第40031號健康諮詢

返回上一頁
  • 患者信息: 47歲

    2.5個月
    乳房左側內上1.5cm 第二期
    淋巴結6中有2轉移
    雌激素陽性100%異黃酮陰性-5%
    Fish檢驗Her2/neu陽性2.47
    組織分化不良
    已作保留手術, 尚未停經
    因為high Her2表現, 醫生告知一clinic tryal by NSABP AC taxol and or
    Herceptin bundled with radiation(owing to BCT case)and taximofin as:
    A randomized trial comparing the safety and efficacy of adriamycin and clophosphamide fllowedby taxol(AC大於T)
    to that of adriamycin and cyclophosphamide
    followed by taxol plus herceptin (AC小於T
    H) in node-positive breast cancer patients
    who have tumors that overexpress her2 (NSABP
    b-31) version 5/16/03

    About 2700 women will take part in this study.
    Have to test in the followgin to be eligible.
    * physical examination
    * pelvic examination (if you have uterus)
    * mammogram
    * blood test
    * chest x-ray
    * bone scan (optional)
    * MUGA scan (for heart functions test)
    * eletrocardiogram (EKG)
    Need to take all tests, many times x-ray,
    antibiotic, and antiallergic drugs like
    dexmethasone, diphenhydramine; and either
    cimetidine,ranitidine, or famotidine.
    Becaused of the nature of randomization, only
    have 1/2 chance to get Herceptin. And,
    can not take femara instead of
    taximofin. 3/4 chance to get rid of recurrence
    possibility against 1/5 permanent heart damage.
    If being done nothing, only have 1/2 chance
    to avoid recurrence.

    敬請賜教是否值損失自愈機能冒險一試, 謝謝

    2003-10-29 12:55:23

  • 黃元惠醫師

    黃元惠 醫師 於 2003-11-19 09:30:10 回覆

    是否接受臨床實驗,考量因素主要有三:1.此疾病是否面臨現有醫學治療方法的極限?﹔2.此疾病是否已經達到末期,隨時面臨死亡的威脅?﹔3.此疾病是否既有治療方法全部都效果不彰?只要具備這三個條件中的任何一個,都可以考慮接受臨床實驗﹔否則的話,請慎重考慮。因為,如同上述合約書所說的,您只有1/2的機會是接受真正新藥治療,有1/2機會是接受安慰劑,得失之間,請三思。
  • 黃元惠醫師

    黃元惠 醫師 一般外科

立即訂閱我們的電子報

掌握最新健康消息!